POMALIDOMIDE BORTEZOMIB AND DEXAMETHASONE (PVD) 21 day cycle

INDICATIONS

Relapsed/Refractory multiple myeloma

This combination is not funded by NHS England. Individual funding must be agreed prior to treatment initiation

TREATMENT INTENT

Disease modification

GENERAL PRE-ASSESSMENT

1. Ensure all the following staging investigations are done:
   - FBC & film
   - Clotting screen
   - U&Es
   - LFTs
   - Calcium
   - Albumin
   - Uric acid
   - CRP
   - Baseline random blood glucose level
   - Virology: HIV, Hepatitis B (including core antibody), and Hepatitis C
   - Calculated creatinine clearance (CrCl), urine protein/creatinine ratio
   - Electrophoresis and immunofixation for quantitation of serum paraprotein and immunoglobulins
   - Serum free light chain assay (Freelite)
   - β2 microglobulin
   - LDH
   - Myeloma FISH should be performed in all patients at diagnosis, and in selected patients at relapse/progression to help guide treatment decisions. Samples should be sent to Wessex Regional Genetics Laboratory (address below)
   - Urine pregnancy testing for pre-menopausal women younger than 55 before each cycle.
   - Group and save
   - Imaging as per NICE/network guidance and clinical presentation
   - Bone marrow aspirate and trephine (with immunophenotyping for kappa/lambda if appropriate)
ADDITIONAL INVESTIGATIONS

1. Plasma viscosity if hyperviscosity suspected
2. If allogeneic transplant an option: Tissue typing of patient and siblings and CMV serology
3. Consent - ensure patient has received adequate verbal and written information regarding their disease, treatment and potential side effects. Document in medical notes all information that has been given.
4. Fertility - all patients should be offered fertility advice, as appropriate.
5. Hydration - fluid intake of at least 3 litres /day should be attempted.
7. Document patient’s performance status
8. Treatment must be agreed at the relevant MDT.

REGIMEN SPECIFIC PRE -ASSESMENT

1. Evaluate for presence of neuropathy. This is usually done by clinical assessment although nerve conduction studies may be useful in occasional patients to document the extent of neurological damage prior to treatment with bortezomib
2. The conditions of the Pomalidomide Celgene Pregnancy Prevention Programme must be fulfilled for all male and female patients. Prescribing and dispensing of pomalidomide must be in line with the Celgene Pregnancy Prevention Programme
3. Clinical assessment of thrombo-embolic risk
4. Baseline lying and standing blood pressure should be recorded prior to administration of cycle #1
# DRUG REGIMEN
Schedule is adapted from OPTIMISM Trial

## CYCLES 1-8

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dosage</th>
<th>Schedule</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pomalidomide</td>
<td>4 mg OD (preferably at night)</td>
<td>Days 1 to 14</td>
</tr>
<tr>
<td>Bortezomib</td>
<td>1.3 mg/m² given S/C bolus</td>
<td>Days 1, 8 and 15</td>
</tr>
<tr>
<td>Dexamethasone</td>
<td>20 mg* PO once daily</td>
<td>Days 1, 2, 8, 9, 15 and 16</td>
</tr>
<tr>
<td></td>
<td>days of and day after each bortezomib dose</td>
<td></td>
</tr>
</tbody>
</table>

## CYCLES 9 onwards

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dosage</th>
<th>Schedule</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pomalidomide</td>
<td>4 mg OD (preferably at night)</td>
<td>Days 1 to 14</td>
</tr>
<tr>
<td>Bortezomib</td>
<td>1.3 mg/m² given S/C bolus</td>
<td>Days 1, 8 only</td>
</tr>
<tr>
<td>Dexamethasone</td>
<td>20 mg* PO once daily</td>
<td>Days 1, 2, 8 and 9</td>
</tr>
<tr>
<td></td>
<td>days of and day after each bortezomib dose</td>
<td></td>
</tr>
</tbody>
</table>

*Consider dose reducing to 10mg in elderly patients >75 years.

At least 72 hours should elapse between consecutive doses of bortezomib.

Triplet therapy can continue until disease progression or unacceptable toxicity

Consider adding clarithromycin 500 mg bd (250mg bd if not tolerating)

Dexamethasone should not be stopped (Unlike lenalidomide-based therapy)

## CYCLE FREQUENCY
Repeat every 21 days

## DOSE MODIFICATIONS

### Haematological toxicity

**BORTEZOMIB:**
Thrombocytopenia due to Bortezomib is transient and very rarely causes significant bleeding. If baseline platelet count is > 7x10⁹/L, then the risk of severe thrombocytopenia is very low

In such patients, FBC should be checked only at the start of the cycle and does not need to be repeated before each dose.

In patients with plts < 7 x 10⁹/L at the start of each cycle, the FBC should be checked before each dose, the drug should be withheld until FBC is through and the dose omitted if the platelets are <
25 x 10⁹/L unless thrombocytopenia is thought to be mainly due to marrow infiltration by myeloma. In those circumstances, consider proceeding with treatment with platelet transfusion support.

In all other circumstances, if these levels are not reached, then treatment should be withheld and subsequent doses reduced by 25% (i.e. from 1.3 mg/m² to 1.0 mg/m² or from 1.0 mg/m² to 0.7 mg/m²).

POMALIDOMIDE:
To initiate a new cycle of Pomalidomide, ANC ≥ 1.0 x 10⁹/L and Platelets ≥ 50 x 10⁹/L

<table>
<thead>
<tr>
<th>Toxicity</th>
<th>Dose Modification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neutropenia:</td>
<td></td>
</tr>
<tr>
<td>ANC &lt; 0.5 x 10⁹/L or Febrile Neutropenia and ANC &lt; 1.0 x 10⁹/L. When ANC return to ≥1 x 10⁹/L</td>
<td>Interrupt Pomalidomide, monitor FBC weekly Resume Pomalidomide at 3 mg OD</td>
</tr>
<tr>
<td>For each subsequent drop ANC &lt; 0.5 x 10⁹/L</td>
<td>Interrupt Pomalidomide</td>
</tr>
<tr>
<td>When ANC ≥ 1.0 x 10⁹/L</td>
<td>Resume Pomalidomide at 1 mg less than previous dose</td>
</tr>
<tr>
<td>Thrombocytopenia:</td>
<td></td>
</tr>
<tr>
<td>Platelets &lt; 25 x 10⁹/L</td>
<td>Interrupt Pomalidomide, monitor FBC weekly Resume Pomalidomide at 3 mg OD</td>
</tr>
<tr>
<td>When Platelets ≥ 50 x 10⁹/L</td>
<td>Resume Pomalidomide</td>
</tr>
<tr>
<td>For each subsequent drop Platelets &lt; 25 x 10⁹/L</td>
<td>Interrupt Pomalidomide</td>
</tr>
<tr>
<td>When Platelets ≥ 50 x 10⁹/L</td>
<td>Resume Pomalidomide at 1 mg less than previous dose</td>
</tr>
</tbody>
</table>

If toxicities occur after dose reductions to 1 mg, then discontinue Pomalidomide. Weekly injections of G-CSF can be administered to keep maintain dose intensity (aim to keep neutrophil counts >1.0)

Peripheral neuropathy
BORTEZOMIB:
If there are symptoms of peripheral neuropathy, the dose reduction schedule must be invoked (see below). The drug should be stopped if symptoms or signs progress despite this.

<table>
<thead>
<tr>
<th>Severity of neuropathy</th>
<th>Dose modification</th>
</tr>
</thead>
<tbody>
<tr>
<td>G1 with no pain or loss of function</td>
<td>None</td>
</tr>
<tr>
<td>G1 with pain or G2</td>
<td>Reduce to 1.0 mg/m² or Change treatment schedule to 1.3 mg/m² once per week</td>
</tr>
<tr>
<td>G2 with pain or G3</td>
<td>Withhold treatment until symptoms of toxicity have resolved. When toxicity resolves re-initiate treatment at 0.7 mg/m² once per week.</td>
</tr>
<tr>
<td>G4 and/or severe autonomic neuropathy</td>
<td>Discontinue</td>
</tr>
</tbody>
</table>

Pomalidomide is structurally similar to thalidomide which is known to induce neuropathy. However, published data suggests that significant neurotoxicity is uncommon.
Non-Haematological

<table>
<thead>
<tr>
<th>Toxicity</th>
<th>Dose Modification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade ≥ 3 non-haematological toxicities considered to be related to</td>
<td>bortezomib should be withheld until symptoms of the toxicity have resolved to Grade 2 or better. Then, it may be reinitiated at a dose reduced by one dose</td>
</tr>
<tr>
<td>bortezomib</td>
<td>level (from 1.3 mg/m² to 1 mg/m², or from 1 mg/m² to 0.7 mg/m²). For bortezomib-related neuropathic pain and/or peripheral neuropathy, hold and/or modify</td>
</tr>
<tr>
<td></td>
<td>bortezomib as outlined in the neuropathy table above.</td>
</tr>
</tbody>
</table>

POMALIDOMIDE

<table>
<thead>
<tr>
<th>Toxicity</th>
<th>Dose Modification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade 3 or 4</td>
<td>Interrupt Pomalidomide</td>
</tr>
<tr>
<td>≤ 2</td>
<td>Resume Pomalidomide at 1 mg less than previous dose</td>
</tr>
</tbody>
</table>

If toxicities occur after dose reductions to 1 mg, then discontinue Pomalidomide.

Renal & Hepatic impairment:

BORTEZOMIB:

<table>
<thead>
<tr>
<th>Renal</th>
<th>Hepatic</th>
</tr>
</thead>
<tbody>
<tr>
<td>For dialysis patients, bortezomib should be given after dialysis. No dose reduction necessary</td>
<td>Bili &gt; 1.5 x ULN: reduce to 0.7 mg/m² in the first treatment cycle. Consider dose escalation to 1.0 mg/m² or further dose reduction to 0.5 mg/m² in subsequent cycles based on patient tolerability.</td>
</tr>
</tbody>
</table>

POMALIDOMIDE:

<table>
<thead>
<tr>
<th>Renal</th>
<th>Hepatic</th>
</tr>
</thead>
<tbody>
<tr>
<td>- No dose adjustment required in renal impairment</td>
<td>Avoid if serum bilirubin &gt; 34 umol/L</td>
</tr>
<tr>
<td>- On haemodialysis days, patients should take pomalidomide following haemodialysis</td>
<td>Careful monitoring is required in hepatic impairment</td>
</tr>
</tbody>
</table>

Venous thromboembolism (VTE): There is an increased risk of thrombosis with pomalidomide. Unless the patient is thought to be at particularly low-risk of thrombosis or high-risk of bleeding, some form of VTE prophylaxis is recommended as follows:

1. Prophylactic low-molecular weight heparin OR
2. Prophylactic NOAC e.g. apixaban 2.5mg bd (check product specific information)

Aspirin can be appropriate for patients with no additional risk factors for thrombosis. It is generally not preferred for higher-risk patients with additional risk factors.

If VTE occurs, pomalidomide can be continued and the patient should be fully anticoagulated according to standard guidelines.
INVESTIGATIONS (at the beginning of each cycle)

- Urine pregnancy testing for pre-menopausal women younger than 55 before each cycle.
- FBC, U&Es, LFTs, Ca\textsuperscript{2+}
- Ig's, paraprotein, usually monthly after first 2 months, Freelite assay if appropriate.
- Consider bone marrow assessment after four cycles for non-secretory Myeloma.
- Clinical assessment of neuropathy should be undertaken and documented prior to each cycle.
- Blood pressure (consider checking for postural drop if symptomatic)
- Consider blood glucose monitoring in patients with diabetes and those with signs of glucose intolerance

CONCURRENT MEDICATIONS

- Allopurinol 300 mg daily for 7 days for cycle 1 only.
- Prophylactic fluconazole 50mg OD
- Prophylactic Acyclovir 200 mg TDS (consider reducing to 200mg BD if CrCl<10ml/min) for the duration of treatment and 3 months post therapy.
- Consider prophylactic co-trimoxazole 960mg OD on M/W/F if heavily pre-treated or previous autograft.
- Proton Pump Inhibitor or H2 antagonist at clinician’s discretion
- Thromboprophylaxis/anticoagulation- as above
- Bone protection as per NSSG Bone Protection protocol MM.3
- Prescribe loperamide if needed for diarrhoea.

Patients on bortezomib should be closely monitored if on CYP3A4-inhibitors (e.g. ketoconazole, ritonavir). The concomitant use of bortezomib with strong CYP3A4-inducers (rifampicin, carabamazepine, and phenytoin, phenobarbital, and St John’s wort) is not recommended as efficacy may be reduced.

If a strong inhibitors of CYP1A2 (e.g. ciprofloxacin, enoxacin and fluvoxamine) is co-administered with pomalidomide, reduce the dose of pomalidomide by 50%.

EMETIC RISK

Low
ADVERSE EFFECTS/REGIMEN SPECIFIC COMPLICATIONS

In the OPTIMISM trials the most commonly reported grade 3 and higher toxicities include neutropenia (42%), and thrombocytopenia (27%), infections (31%).

- **Peripheral neuropathy:** Patients should be advised to report pain hypersensitivity prickling, numbness and paraesthesia. If these occur see above dose reductions and consider use of Amitriptyline, Gabapentin and Pain Team referral. Neuropathy assessment tools are available in DTU. Caution in patients with existing peripheral neuropathy.

- **Dizziness and orthostatic hypotension:** Patients should be advised that Bortezomib may cause orthostatic hypotension and that they should sit upright for a few minutes prior to standing up from a recumbent position. Caution in patients with history of syncope, receiving medications associated with hypotension and patients who are dehydrated. Management of orthostatic/postural hypotension may include adjustment of antihypertensive medicinal products, rehydration or administration of mineralocorticosteroids and/or sympathomimetics. Patients should be instructed to seek medical advice if they experience symptoms of dizziness, light-headedness or fainting spells. Patients who experience dizziness or low blood pressure may benefit from 500ml intravenous 0.9% sodium chloride with each dose of bortezomib.

- **Myelosuppression:** Patients may require dose interruption and/or modification due to thrombocytopenia and/or neutropenia as above. Blood counts to be monitored monthly.

- **Venous thromboembolism (VTE):** There is an increased risk of thrombosis with pomalidomide, and some form of prophylaxis is recommended as above.

- **Gastrointestinal:** Nausea, diarrhoea, vomiting and constipation.

- **Teratogenic:** The Celgene Pregnancy Prevention Programme must be observed for all male and female patients. Prescribing and dispensing of pomalidomide must be in line with the pregnancy prevention programme.

- **Fatigue, confusion, peripheral oedema, pneumonia.**


---

TREATMENT RELATED MORTALITY

<5%
REFERENCES

1. OPTIMISMM: Phase III Trial of Pomalidomide, Bortezomib, Low-Dose Dexamethasone vs Bortezomib, Low-Dose Dexamethasone in Lenalidomide-Exposed RRMM. ASCO 2018


3. Bortezomib (Velcade®) eMC UK Summary of Product Characteristics for, Janssen, 01 March 2017

4. Pomalidomide (IMNOVID) eMC UK Summary of Product Characteristics for Imnovid 4mg, Celgene, 04 May 2018

REVIEW

<table>
<thead>
<tr>
<th>Name</th>
<th>Revision</th>
<th>Date</th>
<th>Version</th>
<th>Review date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Faouzi Djebbari (Haematology Pharmacist)</td>
<td>Protocol write up</td>
<td>July 2018</td>
<td>1.0</td>
<td>June 2019</td>
</tr>
</tbody>
</table>